Provided by Tiger Trade Technology Pte. Ltd.

Oculis

8.70
-0.6400-6.85%
Volume:461.57K
Turnover:4.10M
Market Cap:537.07M
PE:-5.07
High:9.26
Open:9.16
Low:8.69
Close:9.34
52wk High:34.48
52wk Low:8.69
Shares:61.73M
Float Shares:53.44M
Volume Ratio:1.65
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.04
PE(LYR):-3.64

Loading ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
May 16

Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility

TIPRANKS
·
May 15

Press Release: Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

Dow Jones
·
May 15

Oculis Holding Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 13

Stock Track | Oculis Holding Plummets 5.05% Intraday Following Analyst Ratings

Stock Track
·
May 12

Oculis price target raised to $44 from $43 at BofA

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Apogee Therapeutics (APGE)

TIPRANKS
·
May 12

Oculis Holding (OCS) Gets a Buy from Chardan Capital

TIPRANKS
·
May 12

Oculis reports Q1 EPS (49c), consensus (41c)

TIPRANKS
·
May 12

Oculis Holding AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Oculis Holding Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $266.845K Miss $320.000K Estimate

Benzinga Earnings
·
May 12

Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results

TIPRANKS
·
May 12

Switzerland's Oculis Q1 net loss narrows, cash rises

Reuters
·
May 12

Press Release: Oculis Reports Q1 2026 Financial Results and Provides Company Update

Dow Jones
·
May 12

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

GlobeNewswire
·
May 12

Does TransMedics (TMDX) Revenue Growth And OCS Adoption Clarify Or Complicate Its Profitability Path?

Simply Wall St.
·
May 09

Oculis Holding (OCS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 08

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

GlobeNewswire
·
May 07

Earning Preview: Oculis revenue is expected to decrease by 3.77%, and institutional views are bullish

Earnings Agent
·
May 04

Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes

TIPRANKS
·
May 03